Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48


A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response.

Halse H, Caramia F, McLean CA, Wang M, Aw Yeang HX, Keam SP, Behren A, Ly L, Haskett M, Cebon J, McArthur GA, Neeson PJ, Mar VJ.

J Invest Dermatol. 2019 Sep 30. pii: S0022-202X(19)33294-4. doi: 10.1016/j.jid.2019.07.725. [Epub ahead of print]


Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response.

Behren A, Thompson EW, Anderson RL, Ferrao PT.

Front Oncol. 2019 May 7;9:276. doi: 10.3389/fonc.2019.00276. eCollection 2019. No abstract available.


Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes.

Young AR, Duarte JDG, Coulson R, O'Brien M, Deb S, Lopata A, Behren A, Mathivanan S, Lim E, Meeusen E.

Cancers (Basel). 2019 May 16;11(5). pii: E682. doi: 10.3390/cancers11050682.


A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients.

Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, Behren A, Huntington ND, Davis MJ.

Cancer Immunol Res. 2019 Jul;7(7):1162-1174. doi: 10.1158/2326-6066.CIR-18-0500. Epub 2019 May 14.


BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.

Lee EF, Harris TJ, Tran S, Evangelista M, Arulananda S, John T, Ramnac C, Hobbs C, Zhu H, Gunasingh G, Segal D, Behren A, Cebon J, Dobrovic A, Mariadason JM, Strasser A, Rohrbeck L, Haass NK, Herold MJ, Fairlie WD.

Cell Death Dis. 2019 Apr 24;10(5):342. doi: 10.1038/s41419-019-1568-3.


Introduction to Mammalian Genome special issue: inflammation and immunity in cancer.

Behren A, Speidel D, Kollias G, Howell VM.

Mamm Genome. 2018 Dec;29(11-12):691-693. doi: 10.1007/s00335-018-9787-y. No abstract available.


Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.


Characterising the phenotypic evolution of circulating tumour cells during treatment.

Tsao SC, Wang J, Wang Y, Behren A, Cebon J, Trau M.

Nat Commun. 2018 Apr 16;9(1):1482. doi: 10.1038/s41467-018-03725-8.


Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J.

Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018.


The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

da Gama Duarte J, Woods K, Andrews MC, Behren A.

Immunol Cell Biol. 2018 May;96(5):497-506. doi: 10.1111/imcb.12001. Epub 2018 Feb 2. Review.


Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.

Vella LJ, Behren A, Coleman B, Greening DW, Hill AF, Cebon J.

Neoplasia. 2017 Nov;19(11):932-940. doi: 10.1016/j.neo.2017.07.002. Epub 2017 Sep 28.


CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA.

Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16.


PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Tutuka CSA, Andrews MC, Mariadason JM, Ioannidis P, Hudson C, Cebon J, Behren A.

Mol Cancer. 2017 Jun 28;16(1):112. doi: 10.1186/s12943-017-0684-x.


Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.


Systems analysis identifies miR-29b regulation of invasiveness in melanoma.

Andrews MC, Cursons J, Hurley DG, Anaka M, Cebon JS, Behren A, Crampin EJ.

Mol Cancer. 2016 Nov 16;15(1):72.


Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.

Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, Lessene G, Huang DC, Fairlie WD, Strasser A, Herold MJ.

Cell Death Differ. 2016 Dec;23(12):2054-2062. doi: 10.1038/cdd.2016.96. Epub 2016 Sep 30.


Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.

Grasso C, Anaka M, Hofmann O, Sompallae R, Broadley K, Hide W, Berridge MV, Cebon J, Behren A, McConnell MJ.

BMC Cancer. 2016 Sep 9;16(1):726. doi: 10.1186/s12885-016-2759-2.


Identifying and targeting determinants of melanoma cellular invasion.

Jayachandran A, Prithviraj P, Lo PH, Walkiewicz M, Anaka M, Woods BL, Tan B, Behren A, Cebon J, McKeown SJ.

Oncotarget. 2016 Jul 5;7(27):41186-41202. doi: 10.18632/oncotarget.9227.


Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2016 Jun;4(6):552-61. doi: 10.1158/2326-6066.CIR-15-0255. Epub 2016 Apr 4.


Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.

Jayachandran A, Lo PH, Chueh AC, Prithviraj P, Molania R, Davalos-Salas M, Anaka M, Walkiewicz M, Cebon J, Behren A.

BMC Cancer. 2016 Feb 22;16:134. doi: 10.1186/s12885-016-2185-5.


Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J.

J Immunother Cancer. 2016 Feb 16;4:10. doi: 10.1186/s40425-016-0111-7. eCollection 2016.


Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces.

Tsao SC, Vaidyanathan R, Dey S, Carrascosa LG, Christophi C, Cebon J, Shiddiky MJ, Behren A, Trau M.

Sci Rep. 2016 Jan 27;6:19709. doi: 10.1038/srep19709.


Mycoplasma Infection Alters Cancer Stem Cell Properties in Vitro.

Gedye C, Cardwell T, Dimopoulos N, Tan BS, Jackson H, Svobodová S, Anaka M, Behren A, Maher C, Hofmann O, Hide W, Caballero O, Davis ID, Cebon J.

Stem Cell Rev Rep. 2016 Feb;12(1):156-61. doi: 10.1007/s12015-015-9630-8.


Editorial: Cellular and Phenotypic Plasticity in Cancer.

Ferrao PT, Behren A, Anderson RL, Thompson EW.

Front Oncol. 2015 Aug 4;5:171. doi: 10.3389/fonc.2015.00171. eCollection 2015. No abstract available.


Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J.

Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22.


Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.

Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, Dobrovic A.

Sci Rep. 2015 Jun 22;5:11198. doi: 10.1038/srep11198.


Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.

Prithviraj P, Anaka M, McKeown SJ, Permezel M, Walkiewicz M, Cebon J, Behren A, Jayachandran A.

Oncotarget. 2015 Jun 30;6(18):15953-65.


The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS.

Oncoimmunology. 2014 Jul 3;3(7):e946367. eCollection 2014.


The role of circulating microRNA in hepatocellular carcinoma.

Chang-Hao Tsao S, Behren A, Cebon J, Christophi C.

Front Biosci (Landmark Ed). 2015 Jan 1;20:78-104. Review.


Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Wong SQ, Behren A, Mar VJ, Woods K, Li J, Martin C, Sheppard KE, Wolfe R, Kelly J, Cebon J, Dobrovic A, McArthur GA.

Oncotarget. 2015 Jan 20;6(2):1115-27.


Evolving role of tumor antigens for future melanoma therapies.

Andrews MC, Woods K, Cebon J, Behren A.

Future Oncol. 2014 Jun;10(8):1457-68. doi: 10.2217/fon.14.84. Review.


Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma.

Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH, Vella LJ, Goding CR, Cebon J, Behren A.

Oncotarget. 2014 Jul 30;5(14):5782-97.


Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Vella LJ, Andrews MC, Behren A, Cebon J, Woods K.

Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Review.


FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.

Tan B, Anaka M, Deb S, Freyer C, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, Chen W, Mariadason JM.

Oncotarget. 2014 Jan 15;5(1):264-76.


A comprehensive promoter landscape identifies a novel promoter for CD133 in restricted tissues, cancers, and stem cells.

Sompallae R, Hofmann O, Maher CA, Gedye C, Behren A, Vitezic M, Daub CO, Devalle S, Caballero OL, Carninci P, Hayashizaki Y, Lawlor ER, Cebon J, Hide W.

Front Genet. 2013 Oct 29;4:209. doi: 10.3389/fgene.2013.00209. eCollection 2013.


BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J.

J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. No abstract available.


Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors.

Anaka M, Hudson C, Lo PH, Do H, Caballero OL, Davis ID, Dobrovic A, Cebon J, Behren A.

BMC Med Genomics. 2013 Oct 11;6:40. doi: 10.1186/1755-8794-6-40.


BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.

Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA.

Clin Cancer Res. 2013 Sep 1;19(17):4589-98. doi: 10.1158/1078-0432.CCR-13-0398. Epub 2013 Jul 5.


The Ludwig institute for cancer research Melbourne melanoma cell line panel.

Behren A, Anaka M, Lo PH, Vella LJ, Davis ID, Catimel J, Cardwell T, Gedye C, Hudson C, Stan R, Cebon J.

Pigment Cell Melanoma Res. 2013 Jul;26(4):597-600. doi: 10.1111/pcmr.12097. Epub 2013 Apr 11. No abstract available.


Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J.

Eur J Immunol. 2013 Feb;43(2):533-9. doi: 10.1002/eji.201242603. Epub 2012 Dec 5.


FOXP3 is not mutated in human melanoma.

Tan B, Behren A, Anaka M, Vella L, Cebon J, Mariadason JM, Chen W.

Pigment Cell Melanoma Res. 2012 May;25(3):398-400. doi: 10.1111/j.1755-148X.2012.00993.x. Epub 2012 Mar 16. No abstract available.


Stem cell media culture of melanoma results in the induction of a nonrepresentative neural expression profile.

Anaka M, Freyer C, Gedye C, Caballero O, Davis ID, Behren A, Cebon J.

Stem Cells. 2012 Feb;30(2):336-43. doi: 10.1002/stem.786.


Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9.

Mühlen S, Behren A, Iftner T, Simon C.

Int J Oncol. 2010 Aug;37(2):337-45.


Development of an oral cancer recurrence mouse model after surgical resection.

Behren A, Kamenisch Y, Muehlen S, Flechtenmacher C, Haberkorn U, Hilber H, Myers JN, Bergmann Z, Plinkert PK, Simon C.

Int J Oncol. 2010 Apr;36(4):849-55.


Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion.

Behren A, Mühlen S, Acuna Sanhueza GA, Schwager C, Plinkert PK, Huber PE, Abdollahi A, Simon C.

Oncogene. 2010 Mar 11;29(10):1519-30. doi: 10.1038/onc.2009.436. Epub 2009 Dec 21.


AP-1 and ERK1 but not p38 nor JNK is required for CRPV early protein 2-dependent MMP-9 promoter activation in rabbit epithelial cells.

Mühlen S, Behren A, Iftner T, Plinkert PK, Simon C.

Virus Res. 2009 Jan;139(1):100-5. doi: 10.1016/j.virusres.2008.09.007. Epub 2008 Nov 18.


Papillomavirus E2 protein induces expression of the matrix metalloproteinase-9 via the extracellular signal-regulated kinase/activator protein-1 signaling pathway.

Behren A, Simon C, Schwab RM, Loetzsch E, Brodbeck S, Huber E, Stubenrauch F, Zenner HP, Iftner T.

Cancer Res. 2005 Dec 15;65(24):11613-21.


The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells.

Behren A, Binder K, Vucelic G, Herberhold S, Hirt B, Loewenheim H, Preyer S, Zenner HP, Simon C.

Exp Cell Res. 2005 Feb 15;303(2):321-30.


Supplemental Content

Loading ...
Support Center